Physician profile
Michael E Meininger
NPI 1174567010
$8,042.75
in general payments reported to CMS, 2019-2025
35 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $212 · 2021: $879 · 2022: $1,403 · 2023: $1,072 · 2024: $1,396 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,959 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,958.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,244.24 | 2019-2025 | |
| Celgene Corporation | $897.96 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $831.04 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $659.34 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $372.50 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $347.60 | 2019-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $264.10 | 2019-2025 | Entyvio, Eohilia, Gattex |
| E.R. Squibb & Sons, L.L.C. | $229.07 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $222.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $187.14 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $183.58 | 2019-2024 | Dificid, Zinplava |
| Tela Bio, INC. | $166.96 | 2022 | |
| Ironwood Pharmaceuticals, INC | $150.71 | 2019-2024 | |
| Gilead Sciences, INC. | $142.30 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $140.25 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $136.76 | 2019 | |
| Lilly USA, LLC | $126.38 | 2023-2025 | Omvoh |
| Allergan, INC. | $89.39 | 2019 | |
| Celltrion USA INC. | $89.32 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $87.26 | 2019-2023 | Rebyota |
| Motiva USA, LLC | $73.84 | 2025 | |
| Tepha INC | $68.24 | 2019 | |
| Qol Medical, LLC | $43.60 | 2021 | |
| Braintree Laboratories, INC. | $43.04 | 2021 | |
| Redhill Biopharma INC. | $41.21 | 2021-2023 | Talicia |
| Ipsen Biopharmaceuticals, INC | $36.40 | 2025 | Iqirvo |
| Ardelyx, INC. | $33.90 | 2023 | Ibsrela |
| Biocon Biologics INC | $22.44 | 2025 | Yesintek |
| Sanofi US Services INC. | $20.21 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $16.25 | 2023 | Dupixent |
| Evoke Pharma, INC. | $16.16 | 2022 | |
| Alfasigma USA, INC. | $15.59 | 2020 | |
| Daiichi Sankyo INC. | $14.99 | 2022 | |
| Amarin Pharma, INC. | $14.95 | 2021 | |
| Ucb, INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Meininger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.